Literature DB >> 19387612

Translating TCF7L2: from gene to function.

E R Pearson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387612     DOI: 10.1007/s00125-009-1356-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  21 in total

1.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.

Authors:  Struan F A Grant; Gudmar Thorleifsson; Inga Reynisdottir; Rafn Benediktsson; Andrei Manolescu; Jesus Sainz; Agnar Helgason; Hreinn Stefansson; Valur Emilsson; Anna Helgadottir; Unnur Styrkarsdottir; Kristinn P Magnusson; G Bragi Walters; Ebba Palsdottir; Thorbjorg Jonsdottir; Thorunn Gudmundsdottir; Arnaldur Gylfason; Jona Saemundsdottir; Robert L Wilensky; Muredach P Reilly; Daniel J Rader; Yu Bagger; Claus Christiansen; Vilmundur Gudnason; Gunnar Sigurdsson; Unnur Thorsteinsdottir; Jeffrey R Gulcher; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2006-01-15       Impact factor: 38.330

2.  TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.

Authors:  Jose C Florez; Kathleen A Jablonski; Nick Bayley; Toni I Pollin; Paul I W de Bakker; Alan R Shuldiner; William C Knowler; David M Nathan; David Altshuler
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

3.  Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

Authors:  Dominique Dardevet; Mary Courtney Moore; Catherine A DiCostanzo; Ben Farmer; Doss W Neal; Wanda Snead; Margaret Lautz; Alan D Cherrington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

4.  Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes.

Authors:  Stéphane Cauchi; David Meyre; Christian Dina; Hélène Choquet; Chantal Samson; Sophie Gallina; Beverley Balkau; Guillaume Charpentier; François Pattou; Volodymyr Stetsyuk; Raphaël Scharfmann; Bart Staels; Gema Frühbeck; Philippe Froguel
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

5.  The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.

Authors:  K Pilgaard; C B Jensen; J H Schou; V Lyssenko; L Wegner; C Brøns; T Vilsbøll; T Hansen; S Madsbad; J J Holst; A Vølund; P Poulsen; L Groop; O Pedersen; A A Vaag
Journal:  Diabetologia       Date:  2009-03-14       Impact factor: 10.122

6.  Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.

Authors:  Ronald L Prigeon; Shaista Quddusi; Breay Paty; David A D'Alessio
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-05-28       Impact factor: 4.310

7.  Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans.

Authors:  Nicholette D Palmer; Allison B Lehtinen; Carl D Langefeld; Joel K Campbell; Steven M Haffner; Jill M Norris; Richard N Bergman; Mark O Goodarzi; Jerome I Rotter; Donald W Bowden
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

Review 8.  Genome-wide association studies provide new insights into type 2 diabetes aetiology.

Authors:  Timothy M Frayling
Journal:  Nat Rev Genet       Date:  2007-09       Impact factor: 53.242

9.  Islet specific Wnt activation in human type II diabetes.

Authors:  Seung-Hee Lee; Carla Demeterco; Ifat Geron; Annelie Abrahamsson; Fred Levine; Pamela Itkin-Ansari
Journal:  Exp Diabetes Res       Date:  2009-01-20

10.  Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

Authors:  S A Schäfer; O Tschritter; F Machicao; C Thamer; N Stefan; B Gallwitz; J J Holst; J M Dekker; L M 't Hart; L M t'Hart; G Nijpels; T W van Haeften; H U Häring; A Fritsche
Journal:  Diabetologia       Date:  2007-07-28       Impact factor: 10.122

View more
  21 in total

1.  Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

Authors:  Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-27       Impact factor: 4.310

Review 2.  The genetics of type 2 diabetes: what have we learned from GWAS?

Authors:  Liana K Billings; Jose C Florez
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

Review 3.  The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.

Authors:  N van Leeuwen; J J Swen; H-J Guchelaar; L M 't Hart
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans.

Authors:  Erik Ingelsson; Claudia Langenberg; Marie-France Hivert; Inga Prokopenko; Valeriya Lyssenko; Josée Dupuis; Reedik Mägi; Stephen Sharp; Anne U Jackson; Themistocles L Assimes; Peter Shrader; Joshua W Knowles; Björn Zethelius; Fahim A Abbasi; Richard N Bergman; Antje Bergmann; Christian Berne; Michael Boehnke; Lori L Bonnycastle; Stefan R Bornstein; Thomas A Buchanan; Suzannah J Bumpstead; Yvonne Böttcher; Peter Chines; Francis S Collins; Cyrus C Cooper; Elaine M Dennison; Michael R Erdos; Ele Ferrannini; Caroline S Fox; Jürgen Graessler; Ke Hao; Bo Isomaa; Karen A Jameson; Peter Kovacs; Johanna Kuusisto; Markku Laakso; Claes Ladenvall; Karen L Mohlke; Mario A Morken; Narisu Narisu; David M Nathan; Laura Pascoe; Felicity Payne; John R Petrie; Avan A Sayer; Peter E H Schwarz; Laura J Scott; Heather M Stringham; Michael Stumvoll; Amy J Swift; Ann-Christine Syvänen; Tiinamaija Tuomi; Jaakko Tuomilehto; Anke Tönjes; Timo T Valle; Gordon H Williams; Lars Lind; Inês Barroso; Thomas Quertermous; Mark Walker; Nicholas J Wareham; James B Meigs; Mark I McCarthy; Leif Groop; Richard M Watanabe; Jose C Florez
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

5.  Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism.

Authors:  Daniel Savic; Honggang Ye; Ivy Aneas; Soo-Young Park; Graeme I Bell; Marcelo A Nobrega
Journal:  Genome Res       Date:  2011-06-14       Impact factor: 9.043

Review 6.  Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.

Authors:  Christina L Aquilante
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-03

7.  Association testing of TCF7L2 polymorphisms with type 2 diabetes in multi-ethnic youth.

Authors:  D Dabelea; L M Dolan; R D'Agostino; A M Hernandez; J B McAteer; R F Hamman; E J Mayer-Davis; S Marcovina; J M Lawrence; C Pihoker; J C Florez
Journal:  Diabetologia       Date:  2010-11-26       Impact factor: 10.122

8.  Regulation of wingless-type MMTV integration site family (WNT) signalling in pancreatic islets from wild-type and obese mice.

Authors:  J Krützfeldt; M Stoffel
Journal:  Diabetologia       Date:  2009-11-08       Impact factor: 10.122

Review 9.  Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.

Authors:  N K Loganadan; H Z Huri; S R Vethakkan; Z Hussein
Journal:  Pharmacogenomics J       Date:  2016-01-26       Impact factor: 3.550

10.  TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

Authors:  Dennis T Villareal; Heather Robertson; Graeme I Bell; Bruce W Patterson; Hung Tran; Burton Wice; Kenneth S Polonsky
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.